U.S. Court Rules Zyn Marketing Dispute Can Proceed, Rejects Philip Morris International’s Bid to Dismiss

Dec.15.2025
U.S. Court Rules Zyn Marketing Dispute Can Proceed, Rejects Philip Morris International’s Bid to Dismiss
A U.S. federal court in Florida denied Philip Morris International and its subsidiaries’ motion to dismiss, allowing consumers to proceed with claims under the Florida Deceptive and Unfair Trade Practices Act alleging that Zyn nicotine pouches’ “tobacco-free” marketing is misleading. The court held that the allegations do not amount to a fraud claim and may move forward to the merits stage.

Key Points

 

  • A U.S. federal court in Florida denied Philip Morris International’s motion to dismiss, allowing the plaintiffs’ claims under the Florida Deceptive and Unfair Trade Practices Act (FDUTPA) to proceed.
  • Plaintiffs allege that Zyn nicotine pouches were marketed as “tobacco-free,” misleading consumers and downplaying addiction risks.
  • The court held that FDUTPA constitutes an independent cause of action and is not equivalent to the previously dismissed common-law fraud claims.
  • The ruling emphasized that FDUTPA does not require proof of “intent to deceive” and therefore is not subject to the heightened pleading standard of Federal Rule of Civil Procedure 9(b).
  • The plaintiffs’ prior fraud claims were dismissed twice for insufficient pleading detail.

 


2Firsts, December 15, 2025 — According to Law360, U.S. District Judge William P. Dimitrouleas of the Southern District of Florida ruled on December 12 that Philip Morris International (PMI) and its subsidiaries’ motion to dismiss should be denied, allowing claims brought by plaintiff Kovadis Palmer under the Florida Deceptive and Unfair Trade Practices Act (FDUTPA) to proceed.

 

The case arises from a lawsuit filed by Palmer in April 2024 against Philip Morris International and its subsidiary Swedish Match North America LLC. Palmer alleges that the defendants marketed Zyn nicotine pouches as “tobacco-free,” implying a lower risk of addiction, even though the nicotine is derived from tobacco. He contends that the marketing was misleading and that he developed nicotine dependence as a result of using Zyn.

 

Previously, Palmer asserted common-law fraud claims. However, in rulings issued in August 2024 and March 2025, the court dismissed those claims, finding that they failed to meet the particularity requirements for fraud under Federal Rule of Civil Procedure 9(b).

 

In October 2025, Palmer amended his complaint again, withdrawing the fraud claims and instead asserting claims for deceptive or unfair business practices under FDUTPA. The defendants moved once more to dismiss, arguing that the FDUTPA claims were merely a “repackaging” of the earlier fraud allegations and relied on nearly identical factual assertions.

 

The court rejected that argument, explaining that FDUTPA claims do not necessarily depend on allegations of intentional deception. Rather, they focus on whether a deceptive or unfair practice occurred, whether there is a causal connection, and whether actual damages resulted. As such, FDUTPA claims are not subject to Rule 9(b)’s heightened pleading standard for fraud.

 

The court concluded that the FDUTPA claim “is not simply fraud under another name, but advances a new legal theory,” and noted that the allegations do not assert that the defendants acted with intent to mislead consumers.

 

Cover image source: Law360

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China’s E-cigarette Exports Reach $1.694 Billion in Jan–Feb 2026; U.S., UK, Germany Lead, Japan Rises to Fourth
China’s E-cigarette Exports Reach $1.694 Billion in Jan–Feb 2026; U.S., UK, Germany Lead, Japan Rises to Fourth
China Customs Administration released e-cigarette export data for January and February 2025, showing varied monthly performances in 2026.In January, the export value was $940 million, a decrease of 6.2% compared to January 2025's $1.02 billion. In February, the export value was $754 million, a 51.2% increase compared to February 2025's $498 million.
Mar.20 by 2FIRSTS.ai
ITC Keeps Exclusion and Cease-and-Desist Orders in Place Against Stiiizy
ITC Keeps Exclusion and Cease-and-Desist Orders in Place Against Stiiizy
U.S. International Trade Commission has refused to pause the import and sales bans imposed on cannabis vape company Stiiizy while it appeals the agency’s patent infringement ruling in its dispute with Pax Labs.
Apr.07 by 2FIRSTS.ai
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters reported on April 1 that several popular nicotine pouch products still have not been cleared for sale in the United States despite a fast-track review pilot run by the U.S. Food and Drug Administration. Three sources said FDA reviewers have taken a cautious approach because of potential risks to youth and other non-tobacco users, including the possibility of driving nicotine addiction among adults who do not already smoke.
Apr.02 by 2FIRSTS.ai
KT&G Moves Ahead With Oral Nicotine Product Development and Pilot Line Preparation
KT&G Moves Ahead With Oral Nicotine Product Development and Pilot Line Preparation
According to a Korean media report, KT&G is developing a smokeless nicotine product that delivers nicotine through oral absorption and is preparing a pilot production line for research and development.
Apr.08 by 2FIRSTS.ai
Canada Studies UK-Style “Smoke-Free Generation” Tobacco Ban
Canada Studies UK-Style “Smoke-Free Generation” Tobacco Ban
Canada’s federal health minister, Majorie Michel, said she is looking into legislation that would permanently ban the sale of tobacco products to anyone born after 2008. She said Canada has seen the approach recently proposed in the United Kingdom and is reviewing it with partners. Health Canada previously said the Government of Canada has invested C$66 million annually since 2018 to help Canadians quit smoking and reduce the harms of nicotine addiction.
Apr.29 by 2FIRSTS.ai
Shunhao Shares Reports 2025 Revenue of RMB 1.188 Billion, While Q1 2026 Net Profit Rises 49.94% and New Tobacco Operations Continue
Shunhao Shares Reports 2025 Revenue of RMB 1.188 Billion, While Q1 2026 Net Profit Rises 49.94% and New Tobacco Operations Continue
Shunhao Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 1.188 billion, down 21.78% year on year, while net profit attributable to shareholders rose 30.00% to RMB 58.94 million. In the first quarter of 2026, revenue was RMB 291.51 million, down 10.34% year on year, while attributable net profit rose 49.94% to RMB 19.98 million.
Apr.29 by 2FIRSTS.ai